myelofibrosis management: ruxolitinib, fedratinib, transplant
Published 4 years ago • 173 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
2:10
management of ruxolitinib failure in myelofibrosis
-
5:12
ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
14:40
primary myelofibrosis (pmf)
-
1:30:33
lecture 11 - the myelocytic series
-
17:41
for myelofibrosis patients: the latest on promising treatments from top specialist | dr. ruben mesa
-
1:06
fedratinib: mpn-associated myelofibrosis
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis
-
1:52
the role of ruxolitinib in the treatment of early-stage myelofibrosis
-
2:07
fedratinib for myelofibrosis
-
2:54
ruxolitinib in the real world: myelofibrosis
-
1:30
optimal approach to first-line therapy in myelofibrosis
-
1:57
combined navitoclax and ruxolitinib therapy in r/r myelofibrosis
-
1:30
mdm2 inhibitors in myelofibrosis treatment: the addition of navtemadlin to ruxolitinib
-
1:32
panobinostat plus ruxolitinib in myelofibrosis
-
2:10
phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:47
the evolution of myelofibrosis treatment and modern-day management